Haraldsplass Diakonale Sykehus AS
- Address
- Ulriksdal 8, 5009 Bergen, Norway
Haraldsplass Diakonale Sykehus AS - Neurological and Neurodegenerative Disease Research Center
Haraldsplass Diakonale Sykehus AS is a leading clinical research institution specializing in neurological conditions and neurodegenerative diseases. The center demonstrates particular expertise in acute stroke management and dementia research, conducting innovative trials that evaluate novel therapeutic interventions for complex neurological disorders. Their research portfolio reflects a commitment to advancing treatment options for patients facing urgent neurological emergencies as well as progressive cognitive decline.
- Alzheimer's disease therapeutic development, including multiple phase trials evaluating disease-modifying agents and cognitive preservation strategies
- Acute ischemic stroke intervention studies, particularly thrombolytic therapy in patients on anticoagulation
- Dementia with Lewy Bodies research focusing on cognitive, neuropsychiatric, and functional outcomes
- Surgical outcomes research in plastic surgery, investigating hemostatic interventions
The center's neurodegenerative disease program is particularly robust, participating in both pivotal efficacy trials and long-term open-label extension studies for early Alzheimer's disease. This comprehensive approach allows for evaluation of both short-term therapeutic benefits and long-term safety profiles of investigational medications. Their work in acute stroke care addresses critical clinical challenges, such as optimizing thrombolysis protocols for patients receiving Factor Xa inhibitors, representing an important advancement in personalized stroke medicine for an increasingly common patient population.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Helse Fonna HF1active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 112 other sites in Norway
Therapeutic Area Benchmark — Norway
Select a therapeutic area to compare against other sites in Norway.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Norway
Market Share
Country: Norway
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Haraldsplass Diakonale Sykehus AS
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of GSK4527226 in Early Alzheimer's Disease: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2 Study | Glaxosmithkline Research & Development Limited | Phase II | Not Recruiting | May 2024 | Apr 2026 |
IMP list
lock Showing 1 of 15 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Gsk4527226 | 2 | Unknown | 2024-05-07 | 2025-11-25 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.